LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE:PBYI), a development stage
biopharmaceutical company, will host a conference call at 1:30 p.m. PST
(4:30 p.m. EST) on Monday, December 23, 2013, to provide an update on
its clinical trials of PB272 (neratinib) in cancer patients with
activating HER2 mutations. This includes the Company’s ongoing trials of
neratinib in (1) patients with HER2 mutated non-small cell lung cancer;
(2) patients with HER2-negative breast cancer who have a HER2 mutation;
and (3) patients with solid tumors who have an activating HER2 mutation.
Conference Call and Webcast Information
The conference call may be accessed by dialing 1-877-709-8150 for
domestic callers and 1-201-689-8354 for international callers. Please
inform the operator that you would like to join the “Puma Biotechnology
Clinical Update Call.”
The conference call will also be webcast live and accessible through the
Investor Relations section of Puma’s website at http://www.pumabiotechnology.com/ir_events.html
and will be archived there for 30 days following the call. Please visit
Puma’s website several minutes prior to the start of the broadcast to
ensure adequate time for any software download that may be necessary.
About Puma Biotechnology
Puma Biotechnology, Inc. is a development stage biopharmaceutical
company that acquires and develops innovative products for the treatment
of various forms of cancer. The Company focuses on in-licensing drug
candidates that are undergoing or have already completed initial
clinical testing for the treatment of cancer and then seeks to further
develop those drug candidates for commercial use. The Company is
initially focused on the development of PB272 (oral neratinib), a potent
irreversible tyrosine kinase inhibitor, for the treatment of patients
with HER2-positive metastatic breast cancer and patients with non-small
cell lung cancer, breast cancer and other solid tumors that have a HER2
mutation.
Further information about Puma Biotechnology may be found at www.pumabiotechnology.com.
Forward-Looking Statements:
This press release contains forward-looking statements that involve
risks and uncertainties that could cause the Company's actual results to
differ materially from the anticipated results and expectations
expressed in these forward-looking statements. These statements are
based on current expectations, forecasts and assumptions, and actual
outcomes and results could differ materially from these statements due
to a number of factors, which include, but are not limited to, the risk
factors disclosed in the periodic reports filed by the Company with the
Securities and Exchange Commission from time to time. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. The Company assumes
no obligation to update these forward-looking statements, except as
required by law.

Contact: